An international research team led by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects. Their new material could be developed into an antimicrobial drug to treat patients with antibioticresistant infections.
This finding was reported in the scientific journal Nature Communications.
Superbugs that are resistant to antibiotics are a serious health threat. According to the UK Review on Antimicrobial Resistance, superbugs kill around 700,000 people worldwide each year. By 2050, 10 million people could die each year if existing antibiotics continue to lose their effectiveness.
“There is an urgent global need for new antimicrobials that are effective against superbugs. The situation has become more acute because bacteria are starting to develop resistance to the last-line antibiotics, which are given only to patients infected with bacteria resistant to available antibiotics,” said Professor Jackie Y. Ying, Executive Director of IBN.
The research community is trying to develop alternatives to antibiotics using synthetic polymers. However, the antimicrobial polymers developed so far are either too toxic for clinical use, not biodegradable or can only target one type of bacteria.
To address this problem, Dr Yi Yan Yang from IBN brought together a multidisciplinary research team from the US, China and Singapore to develop a new class of antimicrobial polymers called guanidinium-functionalized polycarbonates with a unique killing mechanism that can target a broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic to human cells.
The polymer kills bacteria in the following way. First, the polymer binds specifically to the bacterial cell. Then, the polymer is transported across the bacterial cell membrane into the cytoplasm, where it causes precipitation of the cell contents (proteins and genes), resulting in cell death.
The team tested the polymers on mice infected with five hard-to-treat multidrug-resistant bacteria: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, methicillinresistant Staphylococcus aureu and Pseudomonas aeruginosa. These superbugs are commonly acquired by patients in the hospitals and can cause systemic infections that lead to septic shock and multiple organ failure. The results showed that the bacteria were effectively removed from the mice and no toxicity was observed.
The researchers then further tested the effectiveness of the polymers on mice with two types of systemic infections caused by superbugs: peritonitis (an infection of the stomach’s inner lining) and lung infections from Pseudomonas aeruginosa. The polymers eliminated the bacterial infections in both groups of mice with negligible toxicity.
Dr Yi Yan Yang, Group Leader at IBN said, “We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity. Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections.”
“This study illustrates the potential for this new research field we denote as ‘macromolecular therapeutics’ to create entirely new classes of treatments for multiple diseases,” said Dr James Hedrick, Distinguished Research Staff Member, IBM Research – Almaden, San Jose, California. “In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases. The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance.”
To determine whether the bacteria will develop any resistance to the polymer, the team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research – Almaden to perform genomic analysis. They found that the bacteria did not show any resistance development even after multiple treatments with the polymer.
Learn more: New Molecule Can Kill Five Types of Deadly Drug-Resistant Superbugs
The Latest on: Antimicrobial drug
[google_news title=”” keyword=”Antimicrobial drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antimicrobial drug
- Alabama faces shortage of drug that treats dangerous infection for newbornson June 1, 2023 at 3:28 pm
The medication used to treat syphilis is in short supply in Alabama, threatening efforts to reduce the number of babies exposed to the infection.
- AstraZeneca drug combo gets US nod to treat a type of prostate canceron June 1, 2023 at 12:17 pm
AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant ...
- Pfizer says its experimental antibiotic combo can treat some superbug infectionson June 1, 2023 at 7:27 am
Pfizer Inc said on Thursday data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria.
- Artificial intelligence combats lethal superbug, new antibiotic discoveredon May 31, 2023 at 4:30 am
A new antibiotic that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI).
- Everything you wanted to know about the EU’s pharma reform (but were too afraid to ask)on May 29, 2023 at 9:57 am
It’s not a coincidence that there hasn’t been a discovery of a new class of antibiotic drugs since the 1980s, and that Novartis, Sanofi, and AstraZeneca have all halted their antibiotic research ...
- Antibiotic That Destroys One of World’s Deadliest Superbugs Discovered by AI Supercomputeron May 28, 2023 at 8:25 am
An antibiotic that could be used to treat one of the world's most drug-resistant superbugs has been discovered by AI and supercomputer.
- AI Battles Superbugs: Helps Find New Antibiotic Drug To Combat Drug-Resistant Infectionson May 27, 2023 at 9:03 am
The machine-learning algorithm identified a compound that kills Acinetobacter baumannii, a bacterium that lurks in many hospital settings. Using an artificial intelligence algorithm, researchers at MI ...
- Artificial intelligence helps researchers find new antibiotic to fight deadly superbugon May 27, 2023 at 2:07 am
Researchers report they used an AI algorithm to predict molecules that would neutralize the drug-resistant bacteria Acinetobacter baumannii.
- A new antibiotic, discovered with artificial intelligence, may defeat a dangerous superbugon May 26, 2023 at 11:29 am
Using artificial intelligence, researchers say, they’ve found a new type of antibiotic that works against a particularly menacing drug-resistant bacteria.
- AI zeroes in on an antibiotic drug that can kill a dangerous bacteriaon May 26, 2023 at 5:06 am
Scientists trained a machine-learning model to analyze whether a chemical compound will inhibit the growth of killer bacteria A. baumannii.
via Bing News